Immunoglobulin, glucocorticoid, or combination therapy for multisystem inflammatory syndrome in children: a propensity-weighted cohort study

SARS-CoV-2 neutralizing antibody bebtelovimab – a systematic scoping review and meta-analysis

“…Hence, well-designed real-world evidence observational studies are important to confirm the efficacy and usage of bebtelovimab. Of note, a next-generation monoclonal antibody may play a pivotal role in inducing rapid immunomodulation and limiting the course of illness, for instance, in debilitating multisystem inflammatory syndrome in children associated with COVID-19 considering the vast potential for improved outcomes with the use of single or combination immunotherapies ( 69 , 70 ).…”

Plasma Protein Biomarkers Distinguish Multisystem Inflammatory Syndrome in Children From Other Pediatric Infectious and Inflammatory Diseases

“…Approximately 40% of patients with MIS-C will meet the diagnostic criteria for KD and, due to the overlapping clinical and laboratory features, IVIG was recommended as a first-line treatment for MIS-C. 5 , 13 However, recent evidence has shown that treatment of MIS-C with corticosteroids has the same outcome as IVIG treatment, which is important because corticosteroids are cheap and readily available in low- and middle-income countries. 14 , 15 A diagnostic test to distinguish between these 2 diseases would, therefore, greatly benefit treatment and patient outcome.…”

Immunoglobulin, glucocorticoid, or combined therapy for multisystem inflammatory syndrome in children

“…In further analyses of the BATS cohort in The Lancet Rheumatology , Samuel Channon-Wells and colleagues 10 examined the same research question with more patients and used inverse probability weighting to compare immunomodulatory treatments for MIS-C. The BATS cohort is the largest to date of children with MIS-C who have received immunomodulators and initial treatment with glucocorticoids.…”

“…Channon-Wells and colleagues 10 adjusted for differences between groups through propensity score weighting and subgroup analyses to address confounding bias, given the retrospective and voluntary nature of the data. The gold standard for any treatment intervention would be a large randomised controlled trial, for instance, the RECOVERY trial (ISRCTN50189673), which aims to examine the complexities of MIS-C treatment.…”

“…The gold standard for any treatment intervention would be a large randomised controlled trial, for instance, the RECOVERY trial (ISRCTN50189673), which aims to examine the complexities of MIS-C treatment. Channon-Wells and colleagues 10 suggest the consideration of glucocorticoids as primary treatment instead of intravenous immunoglobulin alone or intravenous immunoglobulin plus glucocorticoids, as the clinical outcomes between treatment groups are similar and the gains using combined treatment appear to be marginal.…”